Key points for investors:
- Strong Q1 2026 financials: total revenue $376.7M (+42% YoY); royalty revenue $240.7M (+43% YoY); adjusted EBITDA ~$229.5M; non-GAAP EPS $1.60 (+~44% YoY).
- Company reaffirmed full-year 2026 and 2026–2028 guidance: total revenue $1.71–1.81B; royalty revenue $1.13–1.17B (projected to exceed $1B for ENHANZE royalties); adjusted EBITDA $1.125–1.205B; non-GAAP EPS $7.75–8.25 (guidance excludes any share-repurchase impact).
- Capital allocation priorities: $1.0B new share repurchase authorization (management expects to repurchase at least $400M in 2026 and target ~3% annual buyback yield going forward), continued investment in ENHANZE/Hypercon/Surf Bio, debt paydown (retire 2027/2028 notes at maturity), and selective M&A (focused on drug-delivery; unlikely to transact outside that area in 2026).
- Durable long-term revenue drivers: (1) continued growth from 10 approved ENHANZE products (management estimates only ~25% of projected royalties realized to date and ~66% of additional projected royalties remain between 2026–2032); (2) up to 13 additional ENHANZE-enabled products projected to enter clinical development (potential launches beginning 2029+); (3) Hypercon platform — 2 Phase I starts expected in H1 2027 with launches targeted ~2030–2031 and potential to reach ~ $1B in royalties by mid-2030s; (4) further launches from additional nominations and new collaboration/licensing agreements (three new deals announced in 2026 including GSK, Vertex, and Oruka).
- Product-level momentum: continued strong commercial performance from DARZALEX SC (Halozyme royalties $129M Q1), VYVGART Hytrulo (royalties $46.3M Q1; strong growth and recent FDA labeling expansion), PHESGO (royalties $30.2M Q1). Recent ENHANZE-enabled launches (OCREVUS ZUNOVO, RYBREVANT FASPRO, OPDIVO, TECENTRIQ) show accelerating uptake and market expansion.
- Hypercon & Surf Bio status: Hypercon integration progressing; clinical supply manufacturing being finalized to support Phase I starts in H1 2027; management plans to invest in manufacturing scale-up to offer end-to-end services. Surf Bio is at an earlier stage (18–24 months behind Hypercon) and uses spray-drying technology.
- Balance sheet and leverage: net leverage ~2.5x at quarter end (reflecting acquisitions); management projects ~1.2x net leverage by end of 2026 after planned buybacks and cash generation.
- Risks / near-term items to monitor: realization of milestone payments from new deals (some milestones are included in guidance), ability to scale Hypercon clinical/commercial manufacturing, timing of ENHANZE pipeline clinical progress and ultimate approvals, and execution of the $400M+ share repurchase plan without altering guidance assumptions.
Sign In
Buy HALO
